A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase of Trial: Phase III
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs Bimekizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Registrational
- Acronyms BE BRIGHT
- Sponsors UCB Biopharma
- 19 Sep 2019 Planned End Date changed from 1 May 2021 to 1 Dec 2022.
- 19 Sep 2019 Planned primary completion date changed from 1 May 2021 to 1 Dec 2022.
- 10 Sep 2018 Status changed from not yet recruiting to recruiting.